ArticlePsychiatric genetics2025
Polygenic risks and cardiovascular treatment effects in severe mental illness.
Article in Psychiatric genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivePatients with severe mental illness (SMI) experience increased cardiovascular risks, leading to reduced life expectancy. Polygenic risk scores (PRS) prediction is promising for assessing cardiovascular risks. This study evaluated the predictive utility of cardiovascular PRS and the impact from risk-reducing interventions among patients with SMI.
methodsUsing samples from the PRIMROSE programme, involving longitudinal cardiovascular interventions within primary care, we calculated seven cardiovascular and two psychiatric (bipolar/schizophrenia) PRS to predict seven corresponding cardiovascular measures [total cholesterol/high-density lipoprotein cholesterol/low-density lipoprotein cholesterol (LDL)/triglyceride/systolic blood pressure/diastolic blood pressure/BMI] assessed at baseline and 12-month follow-up. We applied multiple linear regression models at the two time points and explored the interactions between cardiovascular and psychiatric PRS on these treatment outcomes.
resultsAt baseline, most cardiovascular PRS were associated with the respective measures, except LDL. At follow-up, the participants showed significant improvements in total cholesterol and systolic blood pressure measures; however, these two PRS's prediction effects attenuated toward the null. LDL measures became negatively associated with bipolar PRS posttreatment, though no significant interaction effects were found. Participants in the highest bipolar PRS quartile group had 0.58 mmol/L lower LDL measures than the lowest quartile group at follow-up. These results were robust to potential power reduction, participants' age, sex, prescribed medications, smoking habits, alcohol consumption, and physical activity.
conclusionOur findings underscore the dynamic interplay between genetic risks and treatment effects on cardiovascular outcomes in SMI and warrant careful PRS assessment timing. While the clinical utility of PRS is still evolving, future research should explore different disorders' subtype-specific genetic interactions with interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.